chrisvoncsefalvay/vaers-outcomes huggingface dataset:
A report was received from a health care professional on 12 November 2003, concerning a 51 year old female vaccinee who inadvertently received expired Fluvirin on 11 November 2003. On 11 November 2003, the vaccinee inadvertently received 0.5 ml of expired Fluvirin. The vaccinee did not exhibit any adverse symptoms at the time of reporting. There was insufficient information to determine the reporter's causality assessment. Follow up pending.
Information has been received from a physician concerning a female who on an unspecified date was vaccinated IM with GARDASIL vaccine (yeast) and developed arm pain with stiffness. The physician advised that symptoms resolved on their own and patient had full range of motion when she returned to her office. Additional information is not expected as the physician requested not to be contacted.
Near complete loss of taste and smell.; Near complete loss of taste and smell.; This is a spontaneous report from a contactable nurse (patient).  A 53-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EL3248), via an unspecified route of administration at left arm on 08Jan2021 at 10:00 at single dose for COVID-19 immunization.  The patient medical history included anxiety and depression, both from an unknown date and unknown if ongoing.  The patient's concomitant medication included lamotrigine, fluoxetine, rheum rhaponticum root (ESTROVERA) and gabapentin. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EJ1685), via an unspecified route of administration at right arm on 22Dec2020 at 10:00 at single dose for COVID-19 immunization. On 11Jan2021 at 14:30, the patient experienced near complete loss of taste and smell. The patient underwent lab tests and procedure which included SARS-COV-2 antibody test (Nasal swab): negative on 11Jan2021. The patient outcome of the events was not recovered.
This case was reported by a healthcare professional and described the occurrence of injection site soreness in a 13-year-old male subject who was vaccinated with HAVRIX (GlaxoSmithKline) for prophylaxis. Previous and/or concurrent vaccination included influenza virus vaccine (Novartis) given on 27 December 2007. Concurrent medications included ZOLOFT. On 27 December 2007 at 11:00 the subject received 1st dose of HAVRIX (1 ml, left arm). On 27 December 2007, immediately after vaccination with HAVRIX, the subject experienced injection site soreness. The subject also experienced inappropriate dose of vaccine administration as he received the adult dose. The nurse noted that she thought the soreness at the injection site was from the alcohol not drying completely. At the time of reporting the soreness at the injection site was unresolved.
I have very swollen glands. I did not see this adverse reaction on the websites. The only thing I saw was swollen lymph nodes.
9-10 days post vax, the pt experiences symptoms NOS. The pt was "close to needing a liver transplant" and was transferred to several hospitals. The reporter stated that the pt's diagnosis "sounds like" autoimmune hepatitis. As of 11/13/00, the outcome of the event is ongoing.
soar arm at injection site - unable to lift arm above shoulder - treated with Tylenol -
Several episodes of very pale color & listlessness; responded spontaneously lasted approx 24 hrs post vax; although last episode (?) was on 25APR92;
High heart rate (120-140bpm) while laying down/stationary recorded from 4:30pm - 7:30pm day after injection.  Mild Chest tightness and left arm discomfort, numbness, experienced during that time and continuing into late evening hours (continuing now at 10:30pm)
Patient received Moderna Covid vaccine on 10/21/22 which had expired on 10/19/2022. Vaccines removed from refrigerator and discarded, state notified. Patient notified and made aware that would need dose repeated. Vaers form completed and faxed
blood vessel burst in back of eye and an ophthamologist did surgery to stop the hemorrhaging.  Still recovering. Some sight has returned to the eye.
Sore with knot feeling at injection site - first day.  2nd day still sore and feeling knot but also hot and red. 3rd day still sore, knot, hot,red and now swollen.
After 3 weeks, small rashes along the arms, minor coughing, occasional breathlessness, and mild diarrhea began appearing. Currently about 4 days of these symptoms.   The week immediately after the injection, only minor itching about the body and nothing else. This might all just be a delayed response, but I'd like to note this occurred.
believed vaccine was administered subcutaneosly; It hurt to raise her arm; muscle soreness in arm; A spontaneous report was received from a consumer concerning a female patient who received Moderna's COVID-19 Vaccine (mRNA-1273) and experienced believed vaccine was delivered subcutaneously, vaccination site movement impairment and muscle soreness.   The patient's medical history was not provided. No relevant concomitant medications were reported.   On 20 Jan 2021, approximately 0 days prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (Lot number 012L20A) intramuscularly in the left arm for prophylaxis of COVID-19 infection.  On 20 Jan 2021, the patient believed she was administered the vaccine subcutaneously as she thought the needle was small and noted the vaccinator pinched her arm prior to administration. Following vaccination, she experienced some muscle soreness and it hurt to raise her arm. No treatment information was provided.  Action taken with mRNA-1273 in response to the events was not reported.  The event  believed vaccine was delivered subcutaneously, was considered resolved on 20 Jan 2021. The outcomes of the events vaccination site movement impairment and muscle soreness were unknown.; Reporter's Comments: This case concerns a female patient,  who experienced an incorrect route of product administration, non-serious unexpected event of vaccination site movement impairment and non-serious expected event of myalgia. There were no AEs associated with incorrect route of product administration. The events of vaccination site movement impairment and myalgia occurred 1 day (same day) after first dose of mRNA-1273, lot # 012L20A.  Based on the current available information and temporal association between the use of the product and onset of the events, vaccination site movement impairment and myalgia,  a causal relationship cannot be excluded.
Initial information has been received from a physician via field representative concerning a female patient with an unspecified age, pertinent medical history or drug reactions/allergies. On 03-JAN-2012, the patient was vaccinated with PNEUMOVAX23 (lot H018441) (dose was not reported). No other co-suspects were reported. No concomitant medications were reported. On 04-JAN-2013, the patient had significant "pain, swelling and soreness at the injection site and a lack of mobility. As a treatment, the patient received physical therapy. On an unspecified date, the patient recovered from the events. There was not laboratory test performed. The patient sought medical attention. This is one of several reports from the same source. Additional information has been requested.
This spontaneous report as received from a pharmacy technician refers to a 41 year old patient of unknown gender. Patient's concurrent conditions, medical history, concomitant medications, drug reactions and allergies were not reported. On 08-JUN-2018, the patient was vaccinated with improperly stored dose of VARIVAX (lot # N022979, expiry 23-AUG-2019) for prophylaxis. No adverse effect was reported. The VARIVAX temperature excursion occurred on 14-DEC-2017 and 30-DEC-2017. On 14-DEC-2017, the vaccine was exposed to the temperature of 16.9 degree Fahrenheit (F) for 30 minutes. On 30-DEC-2017, the vaccine was exposed to the temperature of 6 degree Fahrenheit (F) to 14 degree F for 30 minutes. It was reported that the event was because of data logger. No product quality complaint was involved. This is one of the several reports received from the same reporter source. Sender's Comments: US-009507513-1802USA001558.
This spontaneous report as received from a pharmacist refers to a patient of unknown age and gender. Pharmacist reported that a patient was vaccinated on 15-MAY-2013 with GARDASIL (lot # reported as 1397AA, exp Date: 09-APR-2013) (route, dose and indication were not reported). No other concomitant medications were not reported. No adverse effect reported. Additional information has been requested.
no adverse event; patient was administered one dose of PNEUMOVAX 23 in March, 2018 and was given a second dose on 29JAN2020; This spontaneous report received from a pharmacist refers to a patient of unknown age and gender. Concurrent conditions, medical history and concomitant therapies were not reported.  The pharmacist reported that the patient was administered the first dose of Pneumococcal Vaccine, Polyvalent (23-valent)(PNEUMOVAX 23) for prophylaxis, on an unspecified date in March, 2018 (Lot # S027979 has been verified to be a valid lot number for  Pneumococcal Vaccine, Polyvalent (23-valent)(PNEUMOVAX 23), expiration date reported as 31-MAY-2021, but upon internal validation established as 30-MAY-2021).  On 29-JAN-2020, the patient was given a second dose of pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX 23)(inappropriate schedule of product administration). No additional symptoms were reported.
Patient received Covid-19 Vaccine that had expired on 06/30/2022.  No reported symptoms/side effects
BEGINNING THE DAY AFTER ADMINISTRATION OF THE IMMUNIZATIONS, PATIENT EXPERIENCED EXTREME FATIGUE FOR TWO DAYS, REDNESS AND SWELLING OF THE INJECTION SITE - STILL PRESENT BUT SUBSIDING ON 9/19/2020
TERRIBLE HEADACHE; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 18-AUG-2021 for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported.  On an unspecified date, the patient experienced terrible headache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from terrible headache. This report was non-serious.
2 days after receiving  vaccination, patient observed black and blue blotches thru out both legs.  I called her Doctor about it and was advised to bring her to the emergency room.   The Doctor gave her a blood test and sent her home.  The diagnosis was Ecchymosis, post-vaccination reaction.
after 1st shot- 3 days post-vaccination  nausea, fatigue, feverish  after 2nd shot -  nausea and fatigue  comes and goes
No additional adverse effects were reported in the patient; patient received an expired dose of VAQTA; This spontaneous report was received from a registered nurse and refers to a patient of an unknown age and gender. There was no information about the patient's concurrent condition, concomitant medication and medical history provided.  On 11-MAY-2020, the patient was vaccinated with an expired dose of hepatitis a vaccine, inactivated (VAQTA) vial, 25/0.5 (units not provided) for prophylaxis, lot number: S002505 verified as valid, expiration date: 04-APR-2020 (exact dose and route of administration were not provided). No additional adverse effects were reported in the patient. The outcome of the event was unknown.
I am employed and was coerced under threat to take these experimental vaccines, even though I already had natural immunity from prior infection. So, after I took it, some time at night after receiving the injection, I proceeded to have high fever, violent shivering and projectile vomiting. It lasted all night and me and my wife were not certain I'd make it through the night.  The 2 weeks proceeding just left me drained and feeling like a cancer patient. I am now starting to slowly feel like my normal self.  That is if no long-term side effects develop because these vaccines are experimental.
Stiff arm for 1 day. Given Tylenol every 4 hours for 24 hours. No problems with since.
Left upper arm became very itchy and red several hours after getting flu shot. No SOB, wheezing, throat tightening. Pt. reported this to me at a follow-up visit one week later. It resolved with no problems and she did not need to seek medical attention.
pt devel cough, runny nose & fever on 5/26 or 27;tx w/Triaminic, Robitussin & APAP;5/31 devel rash on shoulders & arms;mom describes as tiny red dots;also noted bruises;6/2 to ER w/ more bruises & rash spreading
Administered via subcutaneous route; Menveo administered to a 58 year-old; This case was reported by a pharmacist via call center representative and described the occurrence of intramuscular formulation administered by other route in a 58-year-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA748A, expiry date 20th November 2023) for prophylaxis.   On 1st December 2022, the patient received Menveo (subcutaneous). On 1st December 2022, unknown after receiving Menveo, the patient experienced intramuscular formulation administered by other route and inappropriate age at vaccine administration. On an unknown date, the outcome of the intramuscular formulation administered by other route and inappropriate age at vaccine administration were unknown.   Additional Information: GSK Receipt Date: 02-DEC-2022 Reporter's comment: The pharmacist reported that the patient received a dose of Menveo via subcutaneous route instead of intramuscular.  The reporter consented to follow up. Additional Supportive Information: The fifty-eight-year-old patient received a dose Menveo subcutaneously instead of intramuscularly, which led to inappropriate age at vaccine administration and intramuscular formulation administered by other route.
angioedema of face and eyes-sub-conjunctival edema, purulent drainage from lacrimal ducts, blood shot eyes
Information has been received from a RN concerning a 6 month old white female who on 26Jun06 at 16:15, was vaccinated PO with the first dose of rotavirus G1 G2 G3 G4 P1 reassortant vaccine live (human bovine) (lot 653661/0146F). The RN reported that on 27Jun06 the pt developed rash around her mouth. Medical attention was not sought. At the time of this report, the outcome was unk. Additional information has been requested.
Information has been received from an RN concerning a 5 year old male white pt who on 8/7/00 was vaccinated in the left deltoid with a 1st dose of varicella virus vaccine, a dose of diphtheria toxoid + pertussis vaccine + tetanus toxoid given in the right deltoid. It was reported that for 24 to 48 hours, post vax, there was no swelling, no edema at the varicella virus vaccine live injection site. It was reported that the child developed swelling and induration in the left arm. The child was given Benadryl. The child was then seen in the emergency room that night and it was reported that the swelling increased. The edema seemed to be a cellulitis and antibiotics were started. It was reported that the healthcare professional is not sure the cellulitis was related to the vaccine. "It might have been a bug bite." As of the pt's 8/15/00 follow-up visit, it was reported that the cellulitis was improving. Follow-up from the RN indicated on 8/9/00, after swimming in a pool, the pt's left arm began to swell. The pt was seen in the physician's office which was "questioning a bee sting or questioning an allergic reaction". The pt was then seen in the ER and it was reported to be cellulitis and antibiotics were given. The adverse experiences were considered to be "Other Important Medical Events" by the reporter. The pt subsequently, recovered on 9/8/00.  Follow up on 03/28/2001: "Manufacturer and Lot # for vaccine 1 is not provided."
felt side effects; fatigue; Headache; cold chills; fever 101 F; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (felt side effects), FATIGUE (fatigue), HEADACHE (Headache), CHILLS (cold chills) and PYREXIA (fever 101 F) in a 78-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Mar-2021, the patient experienced VACCINATION COMPLICATION (felt side effects), FATIGUE (fatigue), HEADACHE (Headache), CHILLS (cold chills) and PYREXIA (fever 101 F). At the time of the report, VACCINATION COMPLICATION (felt side effects), FATIGUE (fatigue), HEADACHE (Headache), CHILLS (cold chills) and PYREXIA (fever 101 F) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication reported  No treatment information was provided
Right arm swelling 2 days, after getting shots. (Notified us on 10/17/08). Developed rash, fever. she talked to doctor, not too concerned. Advised her to take TYLENOL and apply ice pack.
Moderna Vaccine was administered after the beyond use date of 30 days at refrigerated temperature. 10/01/2021
Administration error-Patient was given 0.2 mL of the UNDILUTED pediatric (orange top) Covid Vaccine
Severe Diarrhea, Muscle Soreness, Malaise, bilateral arms tingling.
red several centimeter rash for past 2 days. itchy. It is an erythematous confluent plaque with border. It has evolved now into an annular plaque with central clearing
I only had arm pain for 36 hours, and headaches seemed worse than normal. But I have been having chest pains since yesterday morning off and on laying down, and even sometimes up and moving I?ll get light headed and nauseous. But the chest pain is my concern.
Pt developed rash over torso following day after vaccine administered. Rash worsened over week (red patches, itching). Referred to dermatologist given RX clobetasol Propionate and Zyrtec.
Extreme chills, shivering, headache, neck ache, body ached all over. Lasted all night and into the morning, gradually less severe next day, just feel like I have the flu. Stomach pain and cramping.
pt adm 18APR97;recv vax 21APR97;24APR97 pt was noted to have a reddened area on lt upper arm as per nurses not;med consultant described erythematous discoloration of the lt upper arm to lt middle forearm;
1.  Peripheral neuropathy in arms and legs, no treatment, perceived same day as getting the vaccine, symptoms continue. 2.  Arthritis in neck, shoulders and hips, no treatment other than ibuprofen , perceived same day as getting vaccine, symptoms continue. 3.  Metallic taste on tongue and tingling of tongue, no treatment, perceived same day as getting vaccine, symptoms seemed to have subsided. 4.  Stomach muscle fatigue, no treatment, perceived same day as getting vaccine, symptoms including burning sensation continue. 5.  Itchy head, no treatment, perceived same day as getting vaccine, symptoms have lessened over time. 6.  Stuffy head - unable to clear ears, no treatment, perceived same day as getting vaccine, symptoms have lessened over time. 7.  Generalized sore muscles, no treatment, perceived on same day as getting vaccine, symptoms continue. 8.  Generalized aching joints, no treatment, perceived on same day as getting vaccine, symptoms continue. 9.  Enlarged or swollen lymph nodes, no treatment, perceived a few days after getting vaccine, symptoms have lessened over time. 10.  Testicular pain, ice pack as needed, perceived a few days after getting vaccine, symptoms continue.
Mother states approx. 7 to 8 days following immunizations, patient began running a fever that "jumped" from 99 to 103 in approximately 1 hour. Shortly thereafter, patient had a seizure. Taken by ambulance to ED, given further dose of Ibuprofen and IV fluids, then released after several hours with no further adverse effects.
SEVERE FATIGUE, PATIENT FEELING UNWELL AFTER SHOT AND FOR COUPLE OF DAYS, PATIENT EVENTUALLY HOSPITALIZED AND THEN RELEASED.
Patient received 1 dose of H1N1 LAIV on 10/22/2009 and a second dose of H1N1 LAIV on 12/14/2009
Suspected vaccination failure/; shingles on her back, near the wing of her shoulder; fever blisters around her lips together with the shingles outbreak; nerve pain that begins in her tooth, and travels up to her ear and then scalp; dose 1 of Shingrix in August 2018 / dose 2 in April 2020; This case was reported by a consumer and described the occurrence of suspected vaccination failure in a 65-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included shingles (1-2 shingles outbreaks per year).   In April 2020, the patient received the 2nd dose of Shingrix (intramuscular) .5 ml. In August 2018, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. In April 2020, unknown after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced drug dose administration interval too long. On an unknown date, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles, fever blister and nerve pain. On an unknown date, the outcome of the vaccination failure, shingles and fever blister were not recovered/not resolved and the outcome of the nerve pain and drug dose administration interval too long were unknown.   It was unknown if the reporter considered the vaccination failure, shingles, fever blister and nerve pain to be related to Shingrix and Shingrix.  Additional details were provided as follows: The case was reported by patient herself. The patient received both doses of Shingrix in an unknown deltoid. The patient received the 2nd dose of Shingrix later than recommended schedule, which led to lengthening of the vaccination schedule. Specific vaccination dates were unknown. The patient developed shingles on back, near the wing of shoulder. The patient also experienced fever blisters around her lips together with the shingles outbreak, nerve pain that began in tooth and traveled up to her ear and then scalp. It was stated that onset date was unknown but events after the 2nd dose. This case was considered as suspected vaccination failure since the details regarding time to onset and laboratory test confirming shingles were unknown at the time of reporting. The reporter did not consent to follow up.
Increased heart rate; Shortness of breath; This is a spontaneous report from a contactable consumer (patient) reported herself. A 33-year-old non-pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: solution for injection; Lot number: ER8729, Expiration date: Unknown), via an unspecified route of administration, in left arm on 23Apr2021 at 14:30 (at the age of 33-years-old) as dose 2, single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. Patient historical vaccine included first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot number: Eco0150, Expiration date: Unknown), via an unspecified route of administration in right arm on 02Apr2021 at 14:30 as dose 1, single (at the age of 33 years-old) as for covid-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19 and since the vaccination, the patient has not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not receive any other medications within 2 weeks of vaccination. The patient experienced Increased heart rate and shortness of breath on 23Apr2021 at 17:30. The patient underwent lab tests and procedures and which included heart rate: Increased on 23Apr2021. Patient did not receive any treatment for the events. The outcome of the events was unknown.  No follow-up attempts are needed. No further information is expected.